Lenvatinib-induced severe interstitial pneumonia in a patient with hepatocellular carcinoma: A case report

DOI Web Site Web Site 17 References
  • Ikeda Yuki
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Ueno Masayuki
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Takabatake Hiroyuki
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Uenishi Yosuke
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Togawa Ayako
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Hata Ayako
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Mano Toshifumi
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Kayahara Takahisa
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Morimoto Youichi
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
  • Mizuno Motowo
    Department of Gastroenterology and Hepatology, Kurashiki Central Hospital

Bibliographic Information

Other Title
  • レンバチニブにより重篤な間質性肺炎をきたした肝細胞癌の一例
  • レンバチニブ ニ ヨリ ジュウトク ナ カンシツセイ ハイエン オ キタシタ カン サイボウ ガン ノ イチレイ

Search this article

Abstract

<p>A 69-year-old male patient with unresectable hepatocellular carcinoma was treated with lenvatinib, but 3 weeks after starting lenvatinib, he complained of fatigue and body weight loss. We continued lenvatinib at a reduced dose, but his symptoms got worse. One month later, severe dyspnea and hypoxemia developed, and he was admitted to our hospital. Interstitial pneumonia was diagnosed by computed tomography. We discontinued lenvatinib, but his respiratory status deteriorated. He was treated with high-flow nasal cannula and prednisolone, which successfully improved his symptoms. No relapse of interstitial pneumonia was observed during the 1-year follow-up period. This case demonstrates that lenvatinib can cause severe interstitial pneumonia. We should be aware that fatigue or dyspnea can be early symptoms of lenvatinib-induced interstitial pneumonia especially when the symptoms do not improve despite dose reduction or interruption. Prednisolone may be effective for lenvatinib-induced interstitial pneumonia.</p>

Journal

  • Kanzo

    Kanzo 62 (11), 742-748, 2021-11-01

    The Japan Society of Hepatology

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top